MCID: CCN001
MIFTS: 48

Cocaine Dependence

Categories: Mental diseases

Aliases & Classifications for Cocaine Dependence

MalaCards integrated aliases for Cocaine Dependence:

Name: Cocaine Dependence 12 73 54 15 17 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9975
ICD9CM 34 304.2
MeSH 44 D019970
NCIt 50 C34492
SNOMED-CT 67 286934009
ICD10 32 F14.2
UMLS 70 C0600427

Summaries for Cocaine Dependence

Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to cocaine abuse and personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Lamotrigine and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Cocaine dependence is a biopsychosocial disorder characterized by persistent use of cocaine despite... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 cocaine abuse 31.2 SLC6A4 SLC6A3 OPRK1 DRD2 DBH
2 personality disorder 30.9 TPH2 SLC6A4 SLC6A3 DRD3 DRD2 COMT
3 smoking as a quantitative trait locus 3 30.7 CHRNA5 CHRNA3
4 antisocial personality disorder 30.7 SLC6A4 SLC6A3 GABRA2 DRD2 COMT
5 post-traumatic stress disorder 30.6 SLC6A4 POMC DRD2 DBH COMT
6 polysubstance abuse 30.5 DRD3 DRD2 COMT
7 mental depression 30.4 TPH2 SLC6A4 SLC6A3 POMC DRD2 COMT
8 substance abuse 30.4 SLC6A4 SLC6A3 POMC PDYN OPRM1 GABRA2
9 cannabis abuse 30.2 GABRA2 DRD2 COMT
10 borderline personality disorder 30.2 TPH2 SLC6A4 SLC6A3 DRD2 COMT
11 schizoaffective disorder 30.2 SLC6A4 DRD3 DRD2 COMT
12 movement disease 30.1 SLC6A3 DRD3 DRD2 COMT
13 withdrawal disorder 30.1 SLC6A3 POMC PDYN OPRM1 OPRK1
14 bipolar i disorder 30.0 TPH2 SLC6A4 DRD2 DRD1 COMT
15 mood disorder 30.0 TPH2 SLC6A4 SLC6A3 POMC DRD3 DRD2
16 sleep disorder 29.9 SLC6A4 SLC6A3 POMC PDYN COMT
17 attention deficit-hyperactivity disorder 29.9 TPH2 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2
18 alcohol use disorder 29.9 SLC6A4 SLC6A3 OPRM1 GABRA2 DRD3 DRD2
19 bipolar disorder 29.8 TPH2 SLC6A4 SLC6A3 PDYN GABRA2 DRD3
20 psychotic disorder 29.7 TPH2 SLC6A4 SLC6A3 PDYN OPRM1 DRD3
21 pathological gambling 29.7 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 DRD1
22 heroin dependence 29.6 SLC6A4 SLC6A3 PDYN OPRM1 OPRD1 DRD2
23 opiate dependence 29.6 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
24 narcolepsy 29.5 SLC6A4 SLC6A3 PDYN DRD2 DRD1 COMT
25 major depressive disorder 29.4 TPH2 SLC6A4 SLC6A3 POMC OPRM1 DRD3
26 dystonia 29.4 SLC6A3 PDYN DRD3 DRD2 DRD1 DBH
27 opioid abuse 29.3 SLC6A3 POMC PDYN OPRM1 OPRK1 OPRD1
28 drug dependence 29.1 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
29 substance dependence 28.9 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
30 tobacco addiction 28.8 SLC6A4 SLC6A3 PDYN OPRM1 GABRA2 DRD3
31 schizophrenia 28.7 TPH2 SLC6A4 SLC6A3 POMC PDYN OPRM1
32 alcohol dependence 28.3 TPH2 SLC6A4 SLC6A3 POMC PDYN OPRM1
33 inhibited male orgasm 10.4 SLC6A4 SLC6A3
34 alcohol-induced mental disorder 10.4 SLC6A4 DRD2
35 major affective disorder 8 10.4
36 major affective disorder 9 10.4
37 paraphilia disorder 10.4 SLC6A4 DRD2
38 alcoholic psychosis 10.4 SLC6A4 SLC6A3
39 tardive dyskinesia 10.4 DRD3 DRD2 COMT
40 delusional disorder 10.4 SLC6A3 DRD3 DRD2
41 kleptomania 10.3 SLC6A4 DRD2 COMT
42 amphetamine abuse 10.3 SLC6A4 SLC6A3
43 lingual-facial-buccal dyskinesia 10.3 SLC6A3 DRD3 DRD2
44 cyclothymic disorder 10.3 SLC6A4 DRD2 COMT
45 drug psychosis 10.3 SLC6A3 DRD2 COMT
46 drug-induced mental disorder 10.3 SLC6A3 DRD2 COMT
47 obsessive-compulsive personality disorder 10.3 SLC6A4 DRD3 COMT
48 migraine without aura 10.3 SLC6A4 DRD3 DRD2
49 avoidant personality disorder 10.3
50 schizophreniform disorder 10.3 SLC6A3 DRD2 COMT

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 CHRNA3 CHRNA5 CHRNB3 COMT DBH DRD1
2 homeostasis/metabolism MP:0005376 10.25 CHRNA3 COMT DBH DRD1 DRD2 DRD3
3 growth/size/body region MP:0005378 10.22 CHRNA3 DBH DRD1 DRD2 DRD3 GABRA2
4 cardiovascular system MP:0005385 10.18 COMT DBH DRD1 DRD2 DRD3 GABRA2
5 adipose tissue MP:0005375 10.16 DBH DRD1 DRD2 DRD3 NPY2R OPRM1
6 digestive/alimentary MP:0005381 10.11 CHRNA3 DRD1 DRD2 DRD3 NPY2R OPRK1
7 hematopoietic system MP:0005397 10.11 CHRNA5 COMT DRD1 DRD2 FAM53B GABRA2
8 nervous system MP:0003631 10.11 CHRNA3 CHRNA5 COMT DBH DRD1 DRD2
9 endocrine/exocrine gland MP:0005379 10.09 COMT DBH DRD2 NPY2R OPRK1 OPRM1
10 integument MP:0010771 10.07 CHRNA5 DBH DRD1 DRD2 GABRA2 OPRD1
11 no phenotypic analysis MP:0003012 9.56 CHRNA3 DRD2 GABRA2 OPRD1 OPRM1 PDYN
12 taste/olfaction MP:0005394 8.92 DRD2 NPY2R SLC6A3 TPH2

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
2
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
3
Choline Approved, Nutraceutical Phase 4 62-49-7 305
4
Lecithin Experimental Phase 4 8002-43-5
5 Antidepressive Agents Phase 4
6 Quetiapine Fumarate Phase 4 111974-72-2
7 Gastrointestinal Agents Phase 4
8 Sodium Channel Blockers Phase 4
9 Diuretics, Potassium Sparing Phase 4
10 calcium channel blockers Phase 4
11 Calcium, Dietary Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Antimetabolites Phase 4
14 Cytidine Diphosphate Choline Phase 4
15 Lipid Regulating Agents Phase 4
16 Hypolipidemic Agents Phase 4
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
19
Nefazodone Approved, Withdrawn Phase 3 83366-66-9 4449
20
Norepinephrine Approved Phase 3 51-41-2 439260
21
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
22
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
23
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
24
Biperiden Approved, Investigational Phase 2, Phase 3 514-65-8 2381
25
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
26
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
27
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
28
Mirtazapine Approved Phase 2, Phase 3 85650-52-8, 61337-67-5 4205
29
Bupropion Approved Phase 2, Phase 3 34841-39-9, 34911-55-2 444
30
Pergolide Approved, Investigational, Vet_approved, Withdrawn Phase 3 66104-22-1 47811
31
Oxytocin Approved, Vet_approved Phase 2, Phase 3 50-56-6 53477758 439302
32
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
33
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
34
Nicotine Approved Phase 3 54-11-5 942 89594
35
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 52485-79-7 644073 40400
36
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
37
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2
38 Serotonin Uptake Inhibitors Phase 2, Phase 3
39 Narcotics Phase 3
40 Narcotic Antagonists Phase 3
41 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
42 Analgesics, Opioid Phase 2, Phase 3
43 Catechol Phase 2, Phase 3
44 Adjuvants, Immunologic Phase 2, Phase 3
45 Immunologic Factors Phase 2, Phase 3
46 Carbidopa, levodopa drug combination Phase 2, Phase 3
47 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
48 Antiparkinson Agents Phase 2, Phase 3
49 Parasympatholytics Phase 2, Phase 3
50 Muscarinic Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
3 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
4 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
5 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
6 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
7 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
8 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
9 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
10 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
11 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
12 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
13 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
14 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
15 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
16 Bupropion-Enhanced CM for Cocaine Dependence Completed NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
17 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
18 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
19 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
20 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
21 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
22 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
23 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
24 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
25 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
26 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
27 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
28 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
29 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
30 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
31 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
32 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
33 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
34 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
35 Disulfiram for Cocaine Abuse Completed NCT00395850 Phase 2 Disulfiram
36 Modafinil Treatment for Cocaine Dependence and HIV-High Risk Behavior Completed NCT00368290 Phase 2 Modafinil;placebo
37 Tiagabine for the Treatment of Cocaine Dependence Completed NCT00086255 Phase 2 Tiagabine
38 Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence Completed NCT00033033 Phase 2 Reserpine
39 CREST-II: Tiagabine, Sertraline, or Donepezil vs. Unmatched Placebo Completed NCT00015132 Phase 2 Sertraline
40 Naltrexone in Treatment of Cocaine Dependence Completed NCT00015080 Phase 2 Naltrexone
41 A Phase II, Randomized, Double-blind, Placebo-Controlled, Pilot Trial of Topiramate for Alcohol and Comorbid Cocaine Dependence Completed NCT00167245 Phase 2 Topiramate;placebo
42 Modafinil for the Treatment of Cocaine Dependence Completed NCT00100100 Phase 2 Modafinil
43 Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence Completed NCT00033085 Phase 2 Ondansetron
44 Pharmacological Modulation of Cocaine Effects Completed NCT00000201 Phase 2 Selegiline
45 Safety and Efficacy of Selegiline in Outpatient Treatment for Cocaine Completed NCT00000336 Phase 2 Selegiline
46 A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence Completed NCT00249444 Phase 2 Mirtazapine;Placebo
47 ERP-8654 - Integrated Treatment for Cocaine and Mood Disorders Completed NCT00227812 Phase 2 Bupropion
48 CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo Completed NCT00015106 Phase 2 Lamotrigine
49 MPD04961-Methylphendidate Treatment of Cocaine Dependent ADHD Patients Completed NCT00015054 Phase 2 Methylphenidate
50 IV Cocaine Abuse: A Laboratory Model Completed NCT00000215 Phase 2 Pergolide

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

MalaCards organs/tissues related to Cocaine Dependence:

40
Brain, Cortex, Prefrontal Cortex, Pituitary, Amygdala, Thalamus, Temporal Lobe

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 1687)
# Title Authors PMID Year
1
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. 61 54
20170711 2010
2
Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. 61 54
19503018 2009
3
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. 54 61
19720750 2009
4
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. 61 54
19349312 2009
5
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. 61 54
18923396 2009
6
Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 61 54
18321529 2008
7
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? 54 61
15988468 2005
8
Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 54 61
15091312 2004
9
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. 61 54
15545018 2004
10
Dopamine transporter as target for drug development of cocaine dependence medications. 61 54
14612141 2003
11
No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. 54 61
12218660 2002
12
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. 54 61
11092766 2000
13
PET studies of brain monoamine transporters. 61 54
10974156 2000
14
Family-based study of DRD2 alleles in alcohol and drug dependence. 61 54
11054774 2000
15
Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. 61 54
10523822 1999
16
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 61 54
10023512 1999
17
Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? 61 54
9154209 1997
18
No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. 61 54
12893467 1996
19
Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. 54 61
7865100 1994
20
Allelic association of the D2 dopamine receptor gene with cocaine dependence. 54 61
8261891 1993
21
Do comorbid personality disorders in cocaine dependence exacerbate neuroanatomical alterations? A structural neuroimaging study. 61
33716043 2021
22
Altered power spectra in antisocial males during rest as a function of cocaine dependence: A network analysis. 61
33484936 2021
23
Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. 61
33658787 2021
24
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. 61
33460048 2021
25
Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality. 61
33431810 2021
26
Cocaine-Seeking Behavior Induced by Orexin A Administration in the Posterior Paraventricular Nucleus of the Thalamus Is Not Long-Lasting: Neuroadaptation of the Orexin System During Cocaine Abstinence. 61
33708078 2021
27
Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice. 61
33427014 2021
28
A positive association between a polymorphism in the HTR2B gene and cocaine-crack in a French Afro-Caribbean population. 61
30608182 2020
29
Chronic exposure to cocaine is associated with persistent behavioral disturbances. A cross-sectional dimensional study in outpatients with multiple substance use disorders. 61
32748030 2020
30
Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457-Amphetamine Positron Emission Tomography Study. 61
32507390 2020
31
Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L. 61
33165764 2020
32
Histamine H3 receptor gene variants associated with drug abuse in patients with cocaine use disorder. 61
33063610 2020
33
Potent and selective NOP receptor activation reduces cocaine self-administration in rats by lowering hedonic set point. 61
31709687 2020
34
The predictive validity of the progress assessment, a clinician administered instrument for use in measurement-based care for substance use disorders. 61
32711168 2020
35
Bidirectional influence of heroin and cocaine escalation in persons with dual opioid and cocaine dependence diagnoses. 61
33119382 2020
36
Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: Long-lasting blocking of the psychostimulant, discriminative stimulus, and reinforcing effects of cocaine. 61
32710979 2020
37
Cocaine-related DNA methylation in caudate neurons alters 3D chromatin structure of the IRXA gene cluster. 61
33046833 2020
38
Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. 61
33146345 2020
39
Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review. 61
32645315 2020
40
Suicide risk among persons living with HIV. 61
32741212 2020
41
Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Self-Esteem, Personality Traits, and Childhood Abuse. 61
32030810 2020
42
Common and gender-specific associations with cocaine use on gray matter volume: Data from the ENIGMA addiction working group. 61
32857473 2020
43
Neural sensitivity to risk in adults with co-occurring HIV infection and cocaine use disorder. 61
32648056 2020
44
Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration. 61
32389751 2020
45
Motivational factors modulate left frontoparietal network during cognitive control in cocaine addiction. 61
31436010 2020
46
Effective connectivity predicts cognitive empathy in cocaine addiction: a spectral dynamic causal modeling study. 61
32710329 2020
47
Genetic Architecture and Molecular Neuropathology of Human Cocaine Addiction. 61
32457073 2020
48
Are trait impulsivity and exposure to cannabis or alcohol associated with the age of trajectory of cocaine use? A gender-specific dimensional analysis in humans with cocaine dependence diagnosis. 61
31424236 2020
49
GRM8 genotype is associated with externalizing disorders and greater inter-trial variability in brain activation during a response inhibition task. 61
32299001 2020
50
Modulation of neuropeptide Y levels is impaired in crack withdrawal patients. 61
32696889 2020

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 POMC PDYN OPRM1 OPRK1 OPRD1 NPY2R
2
Show member pathways
12.76 SLC6A4 SLC6A3 GABRA2 COMT CHRNB3 CHRNA5
3
Show member pathways
12.55 SLC6A3 DRD3 DRD2 DRD1 COMT CHRNA3
4 12.43 TPH2 POMC OPRM1 DBH COMT
6
Show member pathways
11.85 SLC6A3 PDYN DRD2 DRD1
7 11.77 POMC OPRM1 OPRD1
8
Show member pathways
11.74 DRD3 DRD2 DRD1
9
Show member pathways
11.74 DRD3 DRD2 CHRNA5 CHRNA3
10
Show member pathways
11.59 CHRNB3 CHRNA5 CHRNA3
11
Show member pathways
11.19 TPH2 SLC6A4 SLC6A3 DBH
12
Show member pathways
11.05 SLC6A4 SLC6A3 COMT
13 10.8 POMC NPY2R DRD2
14
Show member pathways
10.59 TPH2 SLC6A4 SLC6A3 DRD3 DRD2 DRD1

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.39 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 NPY2R
2 plasma membrane GO:0005886 10.34 SLC6A4 SLC6A3 PDYN OPRM1 OPRK1 OPRD1
3 cell junction GO:0030054 10.08 SLC6A4 GABRA2 DRD1 CHRNB3 CHRNA5 CHRNA3
4 synapse GO:0045202 10 SLC6A4 PDYN OPRK1 GABRA2 DRD3 DRD2
5 axon GO:0030424 9.97 SLC6A3 OPRM1 GABRA2 DRD2 COMT
6 neuronal cell body GO:0043025 9.97 SLC6A3 PDYN OPRK1 GABRA2 CHRNA3
7 dendrite GO:0030425 9.97 PDYN OPRM1 OPRK1 GABRA2 DRD2 DRD1
8 membrane raft GO:0045121 9.89 SLC6A4 SLC6A3 OPRM1 OPRD1
9 postsynaptic membrane GO:0045211 9.88 OPRD1 GABRA2 COMT CHRNB3 CHRNA5 CHRNA3
10 axon terminus GO:0043679 9.78 PDYN OPRK1 OPRD1 DRD2
11 integral component of plasma membrane GO:0005887 9.77 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 NPY2R
12 GABA-ergic synapse GO:0098982 9.76 GABRA2 DRD3 DRD2
13 non-motile cilium GO:0097730 9.72 NPY2R DRD2 DRD1
14 integral component of postsynaptic membrane GO:0099055 9.72 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
15 integral component of synaptic vesicle membrane GO:0030285 9.71 OPRK1 OPRD1 GABRA2
16 dendrite membrane GO:0032590 9.7 OPRM1 OPRD1 GABRA2
17 acetylcholine-gated channel complex GO:0005892 9.67 CHRNB3 CHRNA5 CHRNA3
18 dopaminergic synapse GO:0098691 9.63 SLC6A3 DRD2 CHRNA5
19 integral component of presynaptic membrane GO:0099056 9.63 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 DRD2
20 spine apparatus GO:0097444 9.56 OPRM1 OPRD1
21 neuron projection GO:0043005 9.32 TPH2 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.26 POMC PDYN OPRM1 OPRK1 OPRD1 NPY2R
2 signal transduction GO:0007165 10.23 POMC OPRM1 OPRK1 OPRD1 NPY2R GABRA2
3 response to drug GO:0042493 10.07 SLC6A4 SLC6A3 DRD3 DRD2 DRD1 COMT
4 ion transmembrane transport GO:0034220 10.02 GABRA2 CHRNB3 CHRNA5 CHRNA3
5 regulation of membrane potential GO:0042391 9.96 GABRA2 CHRNB3 CHRNA5 CHRNA3
6 response to ethanol GO:0045471 9.95 SLC6A3 OPRM1 OPRK1 DRD3 DRD2
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.92 OPRM1 OPRK1 OPRD1 NPY2R
8 chemical synaptic transmission GO:0007268 9.91 PDYN OPRK1 GABRA2 DBH CHRNB3 CHRNA5
9 nervous system process GO:0050877 9.9 GABRA2 CHRNB3 CHRNA5 CHRNA3
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 OPRM1 OPRD1 DRD1
11 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.87 OPRM1 OPRK1 OPRD1
12 response to estrogen GO:0043627 9.87 TPH2 OPRK1 COMT
13 visual learning GO:0008542 9.86 DRD3 DRD2 DRD1 DBH
14 regulation of postsynaptic membrane potential GO:0060078 9.85 GABRA2 CHRNB3 CHRNA5
15 neurotransmitter transport GO:0006836 9.85 SLC6A4 SLC6A3 GABRA2
16 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.83 DRD3 DRD2 DRD1
17 excitatory postsynaptic potential GO:0060079 9.83 OPRM1 DRD2 CHRNB3 CHRNA5 CHRNA3
18 eating behavior GO:0042755 9.82 OPRM1 OPRK1 OPRD1
19 synaptic transmission, cholinergic GO:0007271 9.82 CHRNB3 CHRNA5 CHRNA3
20 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.81 DRD3 DRD2 DRD1
21 negative regulation of cytosolic calcium ion concentration GO:0051481 9.81 OPRM1 DRD3 DRD2
22 response to nicotine GO:0035094 9.81 SLC6A3 DRD2 CHRNB3 CHRNA5
23 behavioral response to cocaine GO:0048148 9.8 OPRK1 DRD3 DRD2
24 response to morphine GO:0043278 9.8 OPRM1 OPRK1 DRD3 DRD2
25 sensory perception GO:0007600 9.79 PDYN OPRM1 OPRK1
26 synaptic transmission, dopaminergic GO:0001963 9.79 DRD3 DRD2 DRD1
27 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.76 NPY2R DRD3 DRD2
28 opioid receptor signaling pathway GO:0038003 9.75 OPRM1 OPRK1 OPRD1
29 dopamine catabolic process GO:0042420 9.74 SLC6A3 DBH COMT
30 dopamine receptor signaling pathway GO:0007212 9.73 DRD2 DRD1
31 negative regulation of adenylate cyclase activity GO:0007194 9.73 DRD3 DRD2
32 response to pain GO:0048265 9.73 DBH COMT
33 estrous cycle GO:0044849 9.73 OPRM1 OPRK1
34 negative regulation of cAMP-mediated signaling GO:0043951 9.73 OPRM1 NPY2R
35 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
36 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 SLC6A3
37 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
38 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
39 maternal behavior GO:0042711 9.71 OPRK1 DBH
40 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD3 DRD2
41 negative regulation of synaptic transmission GO:0050805 9.71 NPY2R DRD2
42 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 DRD3 DRD1
43 monoamine transport GO:0015844 9.71 SLC6A4 SLC6A3
44 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 DRD3 DRD2 DRD1
45 dopamine metabolic process GO:0042417 9.71 DRD3 DRD2 DRD1 COMT
46 adenohypophysis development GO:0021984 9.7 SLC6A3 DRD2
47 behavioral response to ethanol GO:0048149 9.7 OPRM1 DRD2 DBH
48 hyaloid vascular plexus regression GO:1990384 9.69 SLC6A3 DRD2
49 positive regulation of dopamine secretion GO:0033603 9.69 OPRK1 NPY2R
50 regulation of potassium ion transport GO:0043266 9.69 DRD3 DRD2

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10 OPRM1 OPRK1 OPRD1 NPY2R DRD3 DRD2
2 transmembrane signaling receptor activity GO:0004888 9.85 GABRA2 CHRNB3 CHRNA5 CHRNA3
3 ion channel activity GO:0005216 9.81 GABRA2 CHRNB3 CHRNA5 CHRNA3
4 neurotransmitter receptor activity GO:0030594 9.71 GABRA2 CHRNB3 CHRNA5 CHRNA3
5 peptide binding GO:0042277 9.7 OPRM1 OPRK1 OPRD1
6 neuropeptide binding GO:0042923 9.61 OPRM1 OPRK1 OPRD1
7 neurotransmitter transporter activity GO:0005326 9.57 SLC6A4 SLC6A3
8 acetylcholine binding GO:0042166 9.56 CHRNB3 CHRNA3
9 extracellular ligand-gated ion channel activity GO:0005230 9.56 GABRA2 CHRNB3 CHRNA5 CHRNA3
10 monoamine transmembrane transporter activity GO:0008504 9.54 SLC6A4 SLC6A3
11 acetylcholine-gated cation-selective channel activity GO:0022848 9.54 CHRNB3 CHRNA5 CHRNA3
12 acetylcholine receptor activity GO:0015464 9.5 CHRNB3 CHRNA5 CHRNA3
13 receptor serine/threonine kinase binding GO:0033612 9.49 OPRK1 OPRD1
14 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD3 DRD2
15 opioid receptor activity GO:0004985 9.33 OPRM1 OPRK1 OPRD1
16 dopamine binding GO:0035240 9.13 SLC6A3 DRD2 DRD1
17 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD3 DRD2 DRD1

Sources for Cocaine Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....